SkyShowtime Announces Official Launch Date and Content Line-Up
New streaming service SkyShowtime today announced that it will officially launch on 20 September 2022, bringing its premium offering of exclusive and iconic entertainment to millions of homes across Europe for the first time.
A joint venture of Comcast (NASDAQ: CMCSA) —parent company of NBCUniversal and Sky— and Paramount Global (NASDAQ: PARA, PARAA), SkyShowtime will launch in Denmark, Finland, Norway and Sweden on 20 September, before expanding into the Netherlands later this year in Q4. SkyShowtime will continue its roll out across Spain, Portugal, Andorra, and Central & Eastern Europe (CEE) over the coming months and through Q1 2023. CEE markets include Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Kosovo, Montenegro, North Macedonia, Poland, Romania, Serbia, Slovakia and Slovenia. Specific launch dates and pricing in these markets will be announced in the coming months.
SkyShowtime brings together the best entertainment from the world’s greatest studios and storytellers. Featuring thousands of hours of quality entertainment for the whole family, the service will be home to a wide selection of the world’s most highly anticipated series and movies.
It will feature the exclusive television premieres of first-run theatrical films from Paramount Pictures and Universal Pictures, Hollywood’s two oldest studios and which together account for nearly 50% of Hollywood box office.
SkyShowtime will be the home to a selection of new blockbuster films following their theatrical and home entertainment release, including Top Gun: Maverick, Jurassic World Dominion, Minions: The Rise of Gru, The Northman, Sing 2, Sonic the Hedgehog 2, The Lost City, Downton Abbey: A New Era, Nope, Belfast, Ambulance and The Bad Guys.
In addition, SkyShowtime features new premium scripted series, kids and family content and a selection of iconic library titles and box sets from Universal Pictures, Paramount Pictures, Nickelodeon, DreamWorks Animation, Paramount+, SHOWTIME®, Sky Studios and Peacock - all streaming in one place. SkyShowtime will also feature local original programming, documentaries and specials from its markets.
In the Nordics, as part of the partnership with Paramount, SkyShowtime will replace Paramount+, allowing existing and future customers to watch current Paramount+ favourites such as Halo, Yellowstone, The Offer and Star Trek: Strange New Worlds, as well as SHOWTIME® originals Yellowjackets, Dexter: New Blood, Super Pumped: The Battle for Uber, and The First Lady. And for the first time, subscribers will gain access to even more new and exclusive premium series and movies spanning the best of Universal Pictures, Sky Originals and NBCUniversal.
From launch, customers can watch series premieres of highly anticipated SHOWTIME® drama American Gigolo, Sky Originals The Rising, The Fear Index, and The Midwich Cuckoos, as well as Law & Order Season 21 from Peacock. Over the coming months, additional series premieres will include Yellowstone Season 5, Pitch Perfect: Bumper in Berlin, Vampire Academy and SHOWTIME® series Yellowjackets Season 2 and Let The Right One In.
SkyShowtime CEO Monty Sarhan said: “It’s time… for SkyShowtime, — the next great streaming service for Europe. Just months after receiving full regulatory approval, SkyShowtime will officially launch on 20 September 2022. We’re excited for our customers to have exclusive access to the latest series and movie premieres from our iconic and world-renowned studios. We look forward to sharing further details about launch dates for our other markets and bringing SkyShowtime to even more people across Europe.”
SkyShowtime Regional General Manager for Northern Europe Henriette Skov commented: “We’re thrilled to launch SkyShowtime across the Nordics and look forward to offering our customers the very best selection of global series and movies all in one place.”
The service will be available direct-to-consumer via the SkyShowtime app across Apple iOS, tvOS, Android devices, and through the website: www.skyshowtime.com. SkyShowtime’s monthly price will be €6,99 in Finland, SEK 79 in Sweden, NOK 79 in Norway, and DKK 69 in Denmark.
SkyShowtime will also be available through the following distribution partners across its Nordic markets: Allente, RiksTV, Ruutu, Sappa, Strim, Telenor, Tele2, Telia, Telmore and YouSee from Nuuday Group, and TV 2 Play.
Powered by the Peacock platform, SkyShowtime was created specifically for Europe and is dedicated to these markets. With regional offices across its territories, SkyShowtime’s customer-centric focus and local market presence informs its approach to partnerships, content, and marketing. Once launched across more than 20 countries, SkyShowtime’s apps and content will be available in 18 different languages.
The content line up detailed in this press release is Nordic-specific and may vary per market.
For the trailer, please access here: https://youtu.be/ujzpT7FTeeY
For more details, please visit:
Website: www.skyshowtime.com
Newsroom: corporate.skyshowtime.com
LinkedIn: www.linkedin.com/company/skyshowtime
For further information, please email skyshowtimeenquiries@mcsaatchi.com
About SkyShowtime
SkyShowtime is a new streaming service that will launch in the Nordics on 20th September, this year.
A joint venture of Comcast Corporation (NASDAQ: CMCSA) and Paramount Global (NASDAQ: PARA, PARAA), SkyShowtime brings together the combined resources of both companies, direct-to-consumer experience, and the very best entertainment, movies, and original series from the iconic brands of Universal Pictures, DreamWorks, Sky Studios, Peacock, Paramount +, SHOWTIME®, Paramount Pictures and Nickelodeon.
SkyShowtime will be available in more than 20 European markets encompassing 90 million homes. It will be offered in Albania, Andorra, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Finland, Hungary, Kosovo, Montenegro, Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, and Sweden.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220905005022/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom